Biosimilars/General

Genentech sues Centus over Avastin biosimilar

Biosimilars/General | Posted 04/12/2020

Genentech Inc. filed a complaint against Centus in the United States (US) state of Texas on 15 November 2020. It is alleged that Centus’s Equidacent, a biosimilar to Genentech’s Avastin (bevacizumab), infringes 10 US patents. 

Biosimilar toolkit for cancer patients

Biosimilars/General | Posted 27/11/2020

The European Cancer Patient Coalition (ECPC) has launched a biosimilars e-module, or toolkit [1]. This aims to teach patients about the value of biosimilars. 

Alberta Biosimilars Initiative: switching policy updates in Canada

Biosimilars/General | Posted 20/11/2020

The Alberta government in Canada has announced updates to the Alberta Biosimilars Initiative. 

Biosimilar advances for Celltrion Healthcare

Biosimilars/General | Posted 13/11/2020

South Korea-based biotechnology company Celltrion Healthcare announced advances related to their infliximab, omalizumab and adalimumab biosimilars.

GBMA publishes information resources on biosimilars for consumers and carers

Biosimilars/General | Posted 13/11/2020

The Generic and Biosimilar Medicines Association (GBMA), the representative body of generic and biosimilar medicine suppliers in Australia, has recently published information resources for consumers and carers on biosimilars.

International Psoriasis Council releases consensus statement on biosimilars

Biosimilars/General | Posted 30/10/2020

The International Psoriasis Council (IPC) Biosimilar Working Group (BSWG) published their consensus statements for the use of biosimilars in the treatment of patients with psoriasis [1]. 

Australian diabetes organizations issue biosimilars position statement

Biosimilars/General | Posted 16/10/2020

In June 2020, the Australian Diabetes Society, Australian Diabetes Educators Association and Diabetes Australia, published a position statement on the use of biosimilar ‘insulins’ for diabetes.

Sustainable market scorecard represents gold-standard for biosimilar sustainability

Biosimilars/General | Posted 02/10/2020

IQVIA Institute and Medicines for Europe have recently launched Country Scorecards for Biosimilar Sustainability in 12 European countries [1]. The scorecards assess the level of competition, price evolution and volume development for seven key biological molecules – adalimumab, etanercept, infliximab, insulin glargine, insulin lispro, rituximab and trastuzumab – in each country. They also present a sustainability assessment and detail positive policy elements, challenges and solutions for each country.

FDA updates Purple Book database

Biosimilars/General | Posted 25/09/2020

The US Food and Drug Administration (FDA) has updated its searchable Purple Book database to include allergenic, cellular and gene therapy, haematologic and vaccine products.

Country scorecards show biosimilar sustainability

Biosimilars/General | Posted 18/09/2020

Biosimilars are an important component of sustainable health systems as they provide alternatives to originator biological products once those products no longer have market exclusivity. Europe has the world’s largest biosimilar market, accounting for approximately 60% of the global market. European countries therefore serve as valuable examples of successful approaches to biosimilar policy [1]. Nevertheless, across Europe, the level of competition among biosimilars differs widely by country and by molecule, as does the extent of their use and their impact on pricing. Much of this variability can be linked to differences in health system policy elements that contribute to sustainable market conditions for biosimilars.